Treating Patients With T790M-Mutant NSCLC
Thomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).
Challenges Associated With Molecular Targeted Therapies in Lung Cancer
Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.
Actionable Mutations in NSCLC
Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).